Showing results (1491-1500 of 1,518) with videos related to

Sort By:
Pageof 152
ESMO Open|February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trialS Michels, B Massutí, I Vasyliv, et al.
Future Oncology (London, England)|November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine|October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Science Translational Medicine|May 31, 2023
Indian Hedgehog release from TNF-activated renal epithelia drives local and remote organ fibrosisEoin D O'Sullivan, Katie J Mylonas, Cuiyan Xin, et al.
Nature Medicine|January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trialAlicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Science (New York, N.Y.)|February 6, 2025
Retrograde mitochondrial signaling governs the identity and maturity of metabolic tissuesEmily M Walker, Gemma L Pearson, Nathan Lawlor, et al.
The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
JTO Clinical and Research Reports|February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.
Pageof 152